High-end Cellomics Market Snapshot
[216 Pages Report] The High-end Cellomics Market revenue totaled US$ 288.8 Mn in 2021, according to Future Market Insights (FMI) study. The overall sales of high-end cellomics are expected to reach US$ 536.9 Mn by 2031, at a CAGR of 6.4% for 2021 - 2031.
High-end Cellomics allows analyzing how compound interacts with the target at the subcellular level, which delivers insights that can drive go/no-go decisions. Recent developments in drug discovery and high-end cellomics have augmented pressure at the strategic points along the drug discovery pipeline.
Thus, the rising need to determine and study toxicity levels in the initial phase of drug discovery is driving the market growth. The demand for drug discovery also will grow, accounting for nearly 55% of high-end Cellomics revenue in 2021. As per FMI, the high-end Cellomics market represented 1% to 2% of overall sales in US$ 21.09 Bn worth high throughput screening market in 2020.
High-end Cellomics Market Value 2020
Estimated High-end Cellomics Market Value 2021
PerkinElmer Inc., Molecular Devices LLC (Danaher Corporation LLC), Thermofisher Scientific and Yokagawa Electric Corporatoin
2016-2020 High-end Cellomics Demand Outlook Compared to 2021-2031 Forecast
According to Future Market Insights (FMI), the sales of high-end cellomics have grown at a CAGR of 6.4% during 2021- 2031. Due to the rising prevalence of several genetic disorders and neurological diseases, the demand for effective screening methods and techniques has increased in the last decade. This had a positive impact on the high-end cellomics market.
Initiatives undertaken by governments to promote advanced research in biotechnology will increase installation of high-end cellomics instruments for drug discovery applications. Cities of India such as Bangalore, Pune, Hyderabad, and Tamil Nadu have well-established biotechnology research infrastructure recognized globally, which will drive the demand for high-end research instruments.
Apart from India, China, and the U.S., governments of Japan, Brazil, the U.K., and Australia are supporting their domestic biotechnology and bioscience industry through similar initiatives. Factors such as these are expected to create lucrative growth opportunities for manufacturers operating in the global high-end cellomics market
How will Development of Advanced Imaging Systems Augment High-end Cellomics Market Growth?
High-end cellomics has recently acquired substantial traction due to its capacity to investigate features across numerous parts of cell biology and drug discovery and development process. Because of their increased application in life sciences research, these systems have seen technological breakthroughs in automated microscope hardware, sCMOS cameras, confocal optics, oil immersion objective lenses, and throughput capabilities.
Furthermore, these systems have increased software data analysis and data management capabilities. Considering these advancements, the industry players are focusing on introducing new products with these features. Some of the recent launches in this regard include:
In January 2021, Molecular Devices LLC introduced a new high content screening system – ImageXpress Confocal HT.ai High Content HT.ai. This device enables researchers to accelerate their study on phenotypic screening of organoid models. Quick Image acquisition and multiplexing flexibility with high performing lasers are some of the benefits offered by this next-generation high content screening system.
Molecular Devices LLC, in December 2020, introduce water imaging technology for the ImageXpress Micro Confocal High-Content Imaging System. This latest system is developed on existing 3D imaging technology which enables acquisition and analysis of both 3D cell model assays such as spheroids, organoids, and organ-on-chip biology
Availability of such innovative products with associated benefits will lead to an increase adoption, thus fueling the growth of the global high-end cellomics market.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
What are the Key Opportunities for High-end Cellomics Market Players?
High-end cellomics systems are used across a wide range of applications in drug discovery including primary and secondary screening, target identification and validation, toxicity testing, and compound profiling.
For pharmaceutical and biotechnology companies, which is one of the major end-users of these systems, having high-end high content screening equipment increases the total R&D cost of drug development. Also, budgetary constraints among the academic and research institutes lowers the adoption rate of the high-end cellomics systems.
These end-users prefer to outsource HCS services to independent contract research organizations (CROs), due to which the number of CROs offering these services is rising. Charles River Laboratories, Eurofins international are some of the CROs offering high-end cellomics services. Thus, the growing interest in outsourcing services is anticipated to positively drive the sales of the high-end cellomics systems, which in turn provides a lucrative opportunity for market growth.
Will the High Cost of High-end Cellomics Instruments Lower their Adoption?
A high-end cellomics instrument is a set of various analytical methods including automated microscopy, image processing, and visualization tools in one single system. Also, these systems have improved features such as high throughput capacity, confocal optics, sCMOS cameras, water, and oil immersion lens. Hence they are priced on the higher-end.
Apart from the instrumentation cost, installation, maintenance and services costs also add up to the total cost of ownership, thus leading to an increase in the total spending. Academic research institutes, CROS, pharmaceutical and biotechnology companies who are the primary end-users of these systems, are sometimes reluctant for adoption owing to budgetary constraints.
This has made them shift towards other cell imaging analysis equipment such as cell imaging instruments and flow cytometry. This trend is particularly seen in the price-sensitive markets such as India. Thus, the high cost of these instruments coupled with the availability of alternative instruments is expected to create a negative impact on the market growth.
What is the Impact of the COVID-19 Crisis on the Market?
With this unprecedented crisis, the healthcare industry has found itself on the frontline to deal with the medical emergency which has not only ruined the economies across the globe but has also put huge pressure on the healthcare facilities.
The unexpected level of request for the testing kits has pushed the industry players into unexplored regions where their assets are confronted on regular basis. In addition to this, the supplies and demands were jolted by the massive infection spread, which staggered the supplies for manufacturing the high-end cellomics market.
As high-end cellomics instruments are used only for research purposes, the temporary halt in research and development activities has created a sharp reduction in demand for these products. Thus, the high-end cellomics market is expected to witness a short-term negative impact on market growth.
With the lifting of lockdown, reopening of the companies and industries, resuming research and development activities in cell-based research and drug discovery, government initiatives and reviewed market approaches, the high-end cellomics market will register increasing growth 2021 onwards.
Will the U.S. Remain a Key High-end Cellomics Market?
In 2021, the U.S. high-end cellomics market will account for over 86% value share in North America. Demand in the U.S. is primarily driven by a strong regional economy, the presence of refined research and healthcare facilities, and improved attention on overall health and wellbeing.
How will Germany High-end Cellomics Market Fare?
Germany is expected to account for over 21% of the Europe market in 2031. Growing capital and venture investments for cellular research, technological developments in high-end cellomics solutions, cost restraint in pharma R&D, and the presence of key players have led resulted in high growth of the Germany market.
What are the Factors Supporting High-end Cellomics Sales in Australia?
The Australia market will exhibit a 5.0% CAGR throughout the forecast period. The rising prevalence of neurodegenerative diseases such as Alzheimer’s and Parkinson’s is one of the key factors driving the market growth. Similarly, the growing geriatric population is supplementing market growth in Australia.
What will Drive Demand in India High-end Cellomics Market?
The India market account for more than 67% of the sales registered in the South Asia region in 2021. Research activities in the biotechnology and bioscience field are increasing rapidly due to government support and the availability of funds, thus increasing the demand for high-end cellomics in India.
The Government of India is offering 100% foreign direct investment for biotechnology companies that are based outside India, and the GOI is offering public-private partnerships for the companies based in India. Also, the Department of Biotechnology has supported the biotechnology research infrastructure including high-end high content screening system, flow cytometry, imaging microarray, and high-resolution mass spectrometry facilities in Delhi and Mumbai respectively.
What is the Scope for Sales of High-end Cellomics in China?
The market for high-end cellomics in China is exhibiting 7.1% CAGR and is expected to account for 82% of the East Asia market in 2031. Government initiatives to spur biotechnology industry in the region is creating growth opportunities in China. China has included the biotechnology industry as one of the strategic priorities for development in terms of technology. Also, there were about 95 biotech-related deals till June 2020, drawing about USD 12 billion of deals. In 2020, Everest Medicines Ltd and Maxwell Biosciences Co. Ltd. raised USD 310 million in June and USD 279 million respectively. These companies have strong oncology and immunology products in their pipelines, which will require advanced instrumentation such as high-end HCS systems in the drug discovery phase for screening and compound profiling.
What are the Sales Prospects in Drug Discovery?
High-end cellomics demand in drug discovery will consistently rise, registering a high share of 55% in 2021. Increasing support for research and development activities, particularly for rare diseases, and the growing use of informatics in drug discovery led to demand for Drug Discovery.
Why is Demand for High-end Cellomics High in Pharmaceutical & Biotechnology Companies?
Pharmaceutical & biotechnology companies are currently leading the market. Demand in the pharmaceutical & biotechnology companies is expected to grow by 6.2% CAGR. Pharmaceutical & biotechnology companies are using this informatics software widely for pre-clinical research & development, compound screening and lead documentation, target identification, and rationalization of their drug discovery process which is the key factor for propelling the growth of the Pharmaceutical & Biotechnology Companies segment.
Leading players are primarily focusing on market consolidation activities such as mergers, acquisitions, supply distribution partnerships, and launching new products, leading to high competitiveness in this space.
To capitalize on the growing market opportunity, market players are actively focusing on developing high-end cellomics instruments. These systems have increased software data analysis and data management capabilities. Quick image acquisition and multiplexing flexibility with high performing lasers and improved incubation environment are some of the benefits offered by these systems.
ImageXpress Confocal HT.ai High Content HT.ai. (Molecular Devices LLC), ImageXpress Micro Confocal High-Content Imaging System (with water imaging technology)(Molecular Devices LLC), Cell Voyager CV8000 (Yokogawa) are some of the recent launches by the industry players in the global high-end cellomics market.
Scope of the Report
Historical Data Available for
USD Million for Value.
Key Countries Covered
US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa
Key Segments Covered
Application, End-User, and Region
Key Companies Profiled
Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing
Available upon Request
Key Questions Answered in Report
How much is the High-end Cellomics Market worth?
The high-end cellomics market will reach US$ 288.8 Mn in the year 2021 and is expected to surpass US$ 536.9 Mn by 2031.
What is the demand outlook of the High-end Cellomics Market?
High-end cellomics market is projected to register a CAGR of 6.4% during 2021-2031.
What are the key trends shaping High-end Cellomics market?
Growing Investments in cell-based research activities, development of advanced imaging systems, increasing applications in cellular disease modelling systems and growing interest in image-based high content screening are some of the prominent trends which drive the demand for high-end cellomics
What factors are driving demand for High-end Cellomics?
The extensive research and development in drug discovery and are the chief driving factors.
What is the market share of the top players in the High-end Cellomics Market?
The cumulative market share of the top players including PerkinElmer Inc. and Molecular Devices LLC (Danaher Corpoartion LLC) Corporation constitutes around 88.5% of the overall fragmented market.
What are the top 5 countries driving demand for High-end Cellomics?
U.S., China, India, Germany and UK are the top 5 countries that are driving the demand for
At what rate are the sales of High-end Cellomics rising in Europe?
Europe will hold around 30% revenue share in the overall High-end Cellomics Market in 2021. Germany remains the fastest growing country in the Europe market, exhibiting a CAGR of 7.2% over the forecast period of 2021-2031.
At what rate will demand for High-end Cellomics rise in East Asia?
The East Asia market is set to exhibit a CAGR of 6.9% during 2021-2031, the forecast period owing to the continuous research and development in the field of biotechnology which is driving the introduction of innovative and breakthrough technologies, thereby expanding the application areas of biotechnology tools in the region.
Which companies are key manufacturers of High-end Cellomics?
PerkinElmer, Inc., ThermoFisher Scientific, Inc., Molecular Devices LLC (part of Danaher Corporation) and Yokogawa Electric Corporation are the key manufacturers.
What are the key High-end Cellomics Market statistics in Korea and Japan?
Japan high-end cellomics market is expected to account for 10% of global sales through 2031. South Korea will account for 8% of total share through the end of the assessment period.
High-end Cellomics Market by Category
- Academic Research/Basic Research
- Drug Discovery
- Primary & Secondary Screening
- Target Identification & Validation
- Invitro Toxicity Studies
- Compound Profiling
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Independent Contract Research Organizations (CROs)
- North America
- Latin America
- East Asia
- South Asia
- The Middle East and Africa (MEA)